Welcome to our dedicated page for LeonaBio SEC filings (Ticker: LONA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. Securities and Exchange Commission (SEC) filings for LeonaBio, Inc. (NASDAQ: LONA), a clinical-stage biopharmaceutical company focused on metastatic breast cancer and neurodegenerative diseases such as ALS. While recent company communications describe its programs and strategy, formal SEC filings offer detailed legal and financial disclosures about these activities.
Through this page, users can review core periodic reports such as annual reports on Form 10-K and quarterly reports on Form 10-Q, which typically discuss LeonaBio’s clinical-stage pipeline, risk factors related to drug development, and information about licensing arrangements like its exclusive global license (excluding Asia and certain Middle Eastern countries) for lasofoxifene from Sermonix Pharmaceuticals, Inc. These filings may also describe the company’s private placement financings of common stock and warrants that are intended to support clinical and regulatory milestones.
Investors can also look for current reports on Form 8-K, which are used to disclose material events such as the company’s name change from Athira Pharma, Inc. to LeonaBio, Inc., adoption of the LONA ticker, significant licensing transactions, or financing events. In addition, proxy statements on Schedule 14A and related documents can provide information on corporate governance and executive compensation.
This platform enhances access to LeonaBio’s regulatory history by pairing real-time updates from the SEC’s EDGAR system with AI-powered summaries. These summaries are designed to help readers quickly interpret lengthy documents, highlight key sections related to the company’s oncology and neurodegeneration programs, and make it easier to locate information about capital raises, licensing agreements, and other material disclosures.
LeonaBio, Inc. director Michael A. Panzara received a grant of stock options covering 28,000 shares of common stock, with an exercise price of $9.54 per share and expiration on April 8, 2036. These options were granted at no upfront cost as compensation, not through an open-market purchase.
According to the grant terms, the 28,000 option shares are scheduled to vest in equal monthly installments over 24 months from the grant date, as long as Panzara continues to serve as a “Service Provider” under LeonaBio’s 2026 Equity Incentive Plan. Following this grant, he holds 28,000 derivative securities tied to LeonaBio common stock.
LeonaBio, Inc. director Michael A. Panzara received a grant of stock options covering 28,000 shares of common stock, with an exercise price of $9.54 per share and expiration on April 8, 2036. These options were granted at no upfront cost as compensation, not through an open-market purchase.
According to the grant terms, the 28,000 option shares are scheduled to vest in equal monthly installments over 24 months from the grant date, as long as Panzara continues to serve as a “Service Provider” under LeonaBio’s 2026 Equity Incentive Plan. Following this grant, he holds 28,000 derivative securities tied to LeonaBio common stock.
LeonaBio, Inc. reported that its Chief Scientific Officer, Kevin Church, received a grant of stock options covering 300,000 shares of common stock. The options have an exercise price of $9.54 per share and expire on April 8, 2036.
The award was received as a compensation-related grant, not an open-market purchase or sale. According to the grant terms, the options are scheduled to vest monthly over 48 months, as long as Church continues to serve as a Service Provider under LeonaBio’s 2026 Equity Incentive Plan.
LeonaBio, Inc. reported that its Chief Scientific Officer, Kevin Church, received a grant of stock options covering 300,000 shares of common stock. The options have an exercise price of $9.54 per share and expire on April 8, 2036.
The award was received as a compensation-related grant, not an open-market purchase or sale. According to the grant terms, the options are scheduled to vest monthly over 48 months, as long as Church continues to serve as a Service Provider under LeonaBio’s 2026 Equity Incentive Plan.
LeonaBio, Inc. director Grant Pickering received a grant of stock options covering 28,000 shares of common stock. The options have an exercise price of $9.54 per share and expire on April 8, 2036. This is a compensation-related award, not an open-market trade.
The filing shows Pickering holding 28,000 options after the transaction. According to the footnote, the options vest monthly over 24 months from the grant date, contingent on continued service as a Service Provider under LeonaBio’s 2026 Equity Incentive Plan.
LeonaBio, Inc. director Grant Pickering received a grant of stock options covering 28,000 shares of common stock. The options have an exercise price of $9.54 per share and expire on April 8, 2036. This is a compensation-related award, not an open-market trade.
The filing shows Pickering holding 28,000 options after the transaction. According to the footnote, the options vest monthly over 24 months from the grant date, contingent on continued service as a Service Provider under LeonaBio’s 2026 Equity Incentive Plan.
LeonaBio, Inc. director Romano Kelly A received a grant of stock options covering 28,000 shares of common stock on April 9, 2026. The options carry an exercise price of $9.54 per share and expire on April 8, 2036. According to the award terms, the 28,000 underlying shares are scheduled to vest in equal monthly installments over 24 months, contingent on Kelly continuing as a Service Provider under LeonaBio's 2026 Equity Incentive Plan.
LeonaBio, Inc. director Romano Kelly A received a grant of stock options covering 28,000 shares of common stock on April 9, 2026. The options carry an exercise price of $9.54 per share and expire on April 8, 2036. According to the award terms, the 28,000 underlying shares are scheduled to vest in equal monthly installments over 24 months, contingent on Kelly continuing as a Service Provider under LeonaBio's 2026 Equity Incentive Plan.
LeonaBio, Inc. director James A. Johnson received a grant of stock options covering 28,000 shares of common stock. The options carry an exercise price of $9.54 per share and expire on April 8, 2036, and represent compensation rather than an open-market purchase.
These options are scheduled to vest monthly over 24 months on the monthly anniversaries of the grant date, as long as Johnson continues as a Service Provider under LeonaBio’s 2026 Equity Incentive Plan. Following this grant, he holds stock options for 28,000 underlying shares directly.
LeonaBio, Inc. director James A. Johnson received a grant of stock options covering 28,000 shares of common stock. The options carry an exercise price of $9.54 per share and expire on April 8, 2036, and represent compensation rather than an open-market purchase.
These options are scheduled to vest monthly over 24 months on the monthly anniversaries of the grant date, as long as Johnson continues as a Service Provider under LeonaBio’s 2026 Equity Incentive Plan. Following this grant, he holds stock options for 28,000 underlying shares directly.
LeonaBio, Inc. director Joseph Edelman received a grant of stock options covering 28,000 shares of common stock. The options have an exercise price of $9.54 per share and expire on April 8, 2036. The award vests monthly over 24 months, so Edelman earns portions of the grant gradually as he continues to serve as a service provider. Following this grant, he holds stock options for 28,000 underlying shares directly.
LeonaBio, Inc. director Joseph Edelman received a grant of stock options covering 28,000 shares of common stock. The options have an exercise price of $9.54 per share and expire on April 8, 2036. The award vests monthly over 24 months, so Edelman earns portions of the grant gradually as he continues to serve as a service provider. Following this grant, he holds stock options for 28,000 underlying shares directly.
LeonaBio, Inc. reported that Chief Medical Officer Javier San Martin received a grant of stock options covering 350,000 shares of common stock. The options have an exercise price of $9.54 per share, expire on April 8, 2036, and were awarded as compensation.
According to the grant terms, the options vest in equal monthly installments over 48 months from the grant date, so long as San Martin continues to serve as a Service Provider under LeonaBio's 2026 Equity Incentive Plan. This is a derivative award, not an open-market purchase or sale.
LeonaBio, Inc. reported that Chief Medical Officer Javier San Martin received a grant of stock options covering 350,000 shares of common stock. The options have an exercise price of $9.54 per share, expire on April 8, 2036, and were awarded as compensation.
According to the grant terms, the options vest in equal monthly installments over 48 months from the grant date, so long as San Martin continues to serve as a Service Provider under LeonaBio's 2026 Equity Incentive Plan. This is a derivative award, not an open-market purchase or sale.
LeonaBio, Inc. reported that its General Counsel and Chief Compliance Officer, Mark Worthington, received a grant of stock options covering 300,000 shares of common stock. The options have an exercise price of $9.54 per share and expire on April 8, 2036.
The award was classified as a grant or other acquisition of a derivative security, with 300,000 options held directly after the transaction. According to the grant terms, the underlying shares are scheduled to vest monthly over 48 months, subject to his continued service as a provider under LeonaBio’s 2026 Equity Incentive Plan.
LeonaBio, Inc. reported that its General Counsel and Chief Compliance Officer, Mark Worthington, received a grant of stock options covering 300,000 shares of common stock. The options have an exercise price of $9.54 per share and expire on April 8, 2036.
The award was classified as a grant or other acquisition of a derivative security, with 300,000 options held directly after the transaction. According to the grant terms, the underlying shares are scheduled to vest monthly over 48 months, subject to his continued service as a provider under LeonaBio’s 2026 Equity Incentive Plan.
LeonaBio, Inc. reported that its Chief Financial Officer, Robert Renninger, received a grant of stock options covering 300,000 shares of common stock. The options have an exercise price of $9.54 per share and expire on April 8, 2036.
According to the grant terms, these options vest in equal monthly installments over 48 months from the grant date, contingent on Mr. Renninger continuing to serve as a service provider under LeonaBio's 2026 Equity Incentive Plan. Following this award, he holds 300,000 stock options directly.
LeonaBio, Inc. reported that its Chief Financial Officer, Robert Renninger, received a grant of stock options covering 300,000 shares of common stock. The options have an exercise price of $9.54 per share and expire on April 8, 2036.
According to the grant terms, these options vest in equal monthly installments over 48 months from the grant date, contingent on Mr. Renninger continuing to serve as a service provider under LeonaBio's 2026 Equity Incentive Plan. Following this award, he holds 300,000 stock options directly.
LeonaBio, Inc. reported that President and CEO Mark James Litton received a grant of stock options for 750,000 shares of common stock. The options have an exercise price of $9.54 per share and expire on April 8, 2036.
These options were awarded as a compensation grant and will vest in equal monthly installments over 48 months, as long as he continues to serve as a Service Provider under LeonaBio’s 2026 Equity Incentive Plan. Following this award, he holds options covering 750,000 shares.
LeonaBio, Inc. reported that President and CEO Mark James Litton received a grant of stock options for 750,000 shares of common stock. The options have an exercise price of $9.54 per share and expire on April 8, 2036.
These options were awarded as a compensation grant and will vest in equal monthly installments over 48 months, as long as he continues to serve as a Service Provider under LeonaBio’s 2026 Equity Incentive Plan. Following this award, he holds options covering 750,000 shares.